Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Nuvalent (NUVL)
NASDAQ:NUVL
Holding NUVL?
Track your performance easily
NUVL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$61.80 - $113.51
Previous Close$86.86
Volume514.18K
Average Volume (3M)495.97K
Market Cap
$6.17B
Enterprise Value$5.00B
Total Cash (Recent Filing)$1.17B
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.79
Next Earnings
Apr 01, 2025EPS Estimate
-$1.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.48
Shares Outstanding71,052,559
10 Day Avg. Volume381,265
30 Day Avg. Volume495,969
Standard Deviation0.26
R-Squared0.06
Alpha0.06
Financial Highlights & Ratios
Price to Book (P/B)5.50
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-33.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-25.40
Forecast
1Y Price Target
$117.43Price Target Upside34.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Nuvalent News
PremiumCompany Announcements
Nuvalent Elects Grant Bogle as Independent Director
PremiumCompany Announcements
Nuvalent Reports Q3 2024 Progress and Financials
Bulls Say, Bears Say
Bulls Say
Clinical ProgramsBoth NVL-520 and NVL-655 have shown promising clinical data for ROS1 and ALK1 positive NSCLC, respectively, and the potential to address the unmet need in ROS1 and ALK.
Financial PerformanceCash and cash equivalents were $1.2 bn, providing a cash runway into 2028.
Upcoming CatalystThe upcoming clinical data update for NVL-655 in ALK+ non-small cell lung cancer represents a key near-term catalyst for the stock.
Bears Say
Financial RisksKey risks to the 12-month price target include clinical, regulatory, and commercial risks, potential emergence of new competitors, and dilutive financing beyond what has been anticipated.
Market ExpectationsSome 1L ALK value is already priced into NUVL shares, raising questions about whether the predominantly 3L+ data at ESMO can drive upside to NUVL shares.
Regulatory ConcernsThere is more debate around the potential for a single arm path to 2L ALK approval without needing a randomized trial.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
NUVL FAQ
What was Nuvalent’s price range in the past 12 months?
Nuvalent lowest stock price was $61.80 and its highest was $113.51 in the past 12 months.
What is Nuvalent’s market cap?
Currently, no data Available
When is Nuvalent’s upcoming earnings report date?
Nuvalent’s upcoming earnings report date is Apr 01, 2025 which is in 101 days.
How were Nuvalent’s earnings last quarter?
Nuvalent released its earnings results on Nov 12, 2024. The company reported -$1.28 earnings per share for the quarter, missing the consensus estimate of -$0.934 by -$0.346.
Is Nuvalent overvalued?
According to Wall Street analysts Nuvalent’s price is currently Undervalued.
Does Nuvalent pay dividends?
Nuvalent does not currently pay dividends.
What is Nuvalent’s EPS estimate?
Nuvalent’s EPS estimate is -$1.07.
How many shares outstanding does Nuvalent have?
Nuvalent has 65,617,300 shares outstanding.
What happened to Nuvalent’s price movement after its last earnings report?
Nuvalent reported an EPS of -$1.28 in its last earnings report, missing expectations of -$0.934. Following the earnings report the stock price went down -3.602%.
Which hedge fund is a major shareholder of Nuvalent?
Among the largest hedge funds holding Nuvalent’s share is Deerfield Management Company, LP. It holds Nuvalent’s shares valued at 2B.
---
Nuvalent Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$117.43 (34.33% Upside)
$117.43 (34.33% Upside)
Blogger Sentiment
Bullish
NUVL Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 873.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $305.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 1.2%
Last 30 Days ▲ 1.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
15.99%
12-Months-Change
Fundamentals
Return on Equity
-29.57%
Trailing 12-Months
Asset Growth
179.68%
Trailing 12-Months
Company Description
Nuvalent
Nuvalent Inc is a biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets.
---
NUVL Stock 12 Month Forecast
Average Price Target
$117.43
▲(34.33% Upside)
Technical Analysis
Best Analysts Covering NUVL
1 Year
1 Year Success Rate
12/14 ratings generated profit
1 Year Average Return
+73.36%
assigned a buy rating last month
Copying Etzer Darout's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +73.36% per trade.
---